This is a preview of subscription content, log in via an institution to check access.
Reference
Wu D, et al. Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase Cost Effectiveness and Resource Allocation : 21 Jul 2021. Available from: URL: https://doi.org/10.1186/s12962-021-00280-w
Rights and permissions
About this article
Cite this article
Adjuvant chemotherapy cost effective for operable NSCLC in China. PharmacoEcon Outcomes News 884, 2 (2021). https://doi.org/10.1007/s40274-021-7909-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7909-3